Skip to main content
. 2020 Jul 6;81(8):919–941. doi: 10.1002/ddr.21709

TABLE 2.

Therapeutics working on multiple targets

Target Specific effect/target molecule(s) Intervention(s) Status of SARS‐CoV‐2 trial Sponsor/collaborators NCT number
Combined intervention 3CLpro, interferon receptor (IFNAR)

†1 Lopinavir/ritonavir

†2 Ribavirin

†3 Interferon Beta‐1B

Phase 2 The University of Hong Kong, Hospital Authority, Hong Kong NCT04276688
3CLpro, interferon receptor (IFNAR)

†1 Xiyanping injection

†2 Lopinavir/ritonavir, alpha‐interferon nebulization

Not applicable Jiangxi Qingfeng Pharmaceutical Co. Ltd. NCT04275388
ACE2 and spike binding complex, Endosomal acidification

†1 Azithromycin

†2 Chloroquine

Phase 3 Population Health Research Institute NCT04324463
ACE2 and spike binding complex, Endosomal acidification

†1 Azithromycin

†2 Hydroxychloroquine

Phase 4 Chronic Obstructive Pulmonary Disease Trial Network, Denmark NCT04322396
ACE2 and spike binding complex, Endosomal acidification

†1 Hydroxychloroquine + azithromycin

†2 Hydroxychloroquine

Phase 3 Hospital Israelita Albert Einstein, EMS, Hospital do Coracao, Hospital Sirio‐Libanes, Brazilian Research In Intensive Care Network; Hospital do Coracao, Hospital Israelita Albert Einstein, Hospital Sirio‐Libanes, Brazilian Research In Intensive Care Network, EMS NCT04321278, NCT04322123
Endosomal acidification, RdRp

†1 Hydroxychloroquine

†2 Remdesivir

Phase 2, Phase 3 Oslo University Hospital NCT04321616
Spike glycoprotein, 3CLpro

†1 Carrimycin

†2 lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate

Phase 4 Beijing YouAn Hospital, Shenyang Tonglian Group Co., Ltd., Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences, Huangshi Central Hospital, Shenyang Pharmaceutical University, First Affiliated Hospital of Chongqing Medical University, The Second Affiliated Hospital of Harbin Medical University, No. 2 People's Hospital of Fuyang City, First Affiliated Hospital Bengbu Medical College, Renmin Hospital of Wuhan University, The Sixth People's Hospital of Shenyang, Nanyang Central Hospital NCT04286503
Spike glycoprotein, 3CLpro

†1 Abidol hydrochloride

†2 Oseltamivir

†3 Lopinavir/ritonavir

Phase 4 Tongji Hospital NCT04255017

Note: †1, †2, and †3 are different arms of parallel intervention.